FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or HER2-ultralow Breast Cancer By Ogkologos - March 6, 2025 236 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DESTINY-Breast06 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Breast Cancer Patient Is Accused of Having “Body Image Issues” After... March 5, 2021 EMA Recommends Extension of Indications for Pembrolizumab to Malignant Pleural Mesothelioma December 11, 2024 Pembrolizumab Demonstrates Robust, Durable Antitumour Activity and Promising Survival in Advanced... July 21, 2021 Mom Thinks Baby Died Until Firefighters Say The Family Dog Made... June 4, 2019 Load more HOT NEWS Germline Pathogenic Variants in CDH1, BRCA2, CHEK2, ATM, and PALB2 Associated... FDA Approves Polatuzumab Vedotin-piiq for Previously Untreated Diffuse Large B-Cell Lymphoma,... Optimistic targets aren’t enough – this is what we need to... Inspired By Her Mom’s Breast Cancer Battle, Girl Sells ‘Cancer Bears’...
